Skip to main content
SpringerLink
Log in

Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

S-1 plus docetaxel is the standard postoperative adjuvant chemotherapy regimen for patients with stage III gastric cancer in Japan, which has increased the use of docetaxel. One of the most common adverse events of docetaxel, which is widely used to treat several malignancies, is fluid retention. Conversely, the most worrisome cause of ascites in patients who receive adjuvant chemotherapy is recurrence. Sometimes, the differential diagnosis of ascites is difficult if ascitic cytology is negative. In this study, we presented the case of a patient with massive ascites that appeared during adjuvant chemotherapy with S-1 plus docetaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  Google Scholar 

  2. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  Google Scholar 

  3. Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.

    Article  CAS  Google Scholar 

  4. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003;14(Suppl 2):ii41–4.

    Article  Google Scholar 

  5. Béhar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol. 1996;43:653–8.

    Article  Google Scholar 

  6. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16:3426–32.

    Article  CAS  Google Scholar 

  7. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci. 2015;106:497–504.

    Article  CAS  Google Scholar 

  8. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16:187–96.

    Article  CAS  Google Scholar 

  9. Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs. 1996;7(Suppl 2):25–8.

    Article  CAS  Google Scholar 

  10. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–55.

    Article  CAS  Google Scholar 

  11. Brady PG, Peebles M, Goldschmid S. Role of laparoscopy in the evaluation of patients with suspected hepatic or peritoneal malignancy. Gastrointest Endos. 1991;37:27.

    Article  CAS  Google Scholar 

  12. Coupland GA, Townend DM, Martin CJ. Peritoneoscopy-use in assessment of intra-abdominal malignancy. Surgery. 1981;89:645–9.

    CAS  PubMed  Google Scholar 

  13. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215–20.

    Article  CAS  Google Scholar 

  14. Singer EA, Srinivasan R. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol. 2012;30(4 Suppl):S15–9.

    Article  CAS  Google Scholar 

  15. Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253–9.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Joe Barber Jr., Ph.D., from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan

    Kunihiro Tsuji, Yosuke Kito, Saori Miyajima & Hisashi Doyama

  2. Department of Pharmacy, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan

    Miwa Yonezawa, Anna Kubo & Kahori Ushijima

Authors
  1. Kunihiro Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yosuke Kito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saori Miyajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miwa Yonezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kahori Ushijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hisashi Doyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kunihiro Tsuji.

Ethics declarations

Conflict of interest

Kunihiro Tsuji, Yosuke Kito, Saori Miyagima, Miwa Yonezawa, Anna Kubo, Kahori Ushijima, and Hisashi Doyama declare that they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from patient for being included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsuji, K., Kito, Y., Miyajima, S. et al. Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel. Clin J Gastroenterol 14, 84–87 (2021). https://doi.org/10.1007/s12328-020-01265-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-020-01265-7

Keywords

Search

Navigation